Cue Biopharma, Inc. (CUE)
Largest Insider Buys in Sector
CUE Stock Price History Chart
CUE Stock Performance
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; …
Insider Activity of Cue Biopharma, Inc.
Over the last 12 months, insiders at Cue Biopharma, Inc. have bought $30,900 and sold $0 worth of Cue Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Cue Biopharma, Inc. have bought $962,605 and sold $1.49M worth of stock each year.
Highest buying activity among insiders over the last 12 months: PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) — $61,800.
The last purchase of 30,000 shares for transaction amount of $30,900 was made by PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) on 2024‑12‑16.
List of Insider Buy and Sell Transactions, Cue Biopharma, Inc.
| 2024-12-16 | CHIEF EXECUTIVE OFFICER | 30,000 0.0473% | $1.03 | $30,900 | +1.47% | |||
| 2023-08-25 | PRESIDENT AND CSO | 4,000 0.0088% | $2.76 | $11,040 | -26.16% | |||
| 2023-08-14 | CHIEF EXECUTIVE OFFICER | 3,000 0.0065% | $2.86 | $8,580 | -31.51% | |||
| 2023-03-23 | Sale | director | 9,325 0.0208% | $3.28 | $30,586 | -14.55% | ||
| 2022-05-27 | 28,000 0.0769% | $3.75 | $105,000 | -19.17% | ||||
| 2022-05-23 | 55,000 0.1455% | $3.34 | $183,700 | -12.61% | ||||
| 2022-03-31 | 735,000 2.0277% | $4.76 | $3.5M | -36.07% | ||||
| 2021-11-16 | Sale | director | 1,361 0.0046% | $18.02 | $24,525 | -77.86% | ||
| 2021-11-15 | Sale | President and CSO | 8,000 0.0257% | $18.05 | $144,400 | -78.74% | ||
| 2021-11-15 | Sale | director | 18,815 0.0599% | $17.92 | $337,165 | -78.74% | ||
| 2021-11-11 | Sale | President and CSO | 20,000 0.0634% | $15.07 | $301,354 | -74.37% | ||
| 2021-10-01 | Sale | CHIEF FINANCIAL OFFICER | 1,251 0.0039% | $14.21 | $17,783 | -66.60% | ||
| 2021-09-24 | CHIEF EXECUTIVE OFFICER | 3,400 0.011% | $14.72 | $50,051 | -65.45% | |||
| 2021-09-23 | Sale | PRESIDENT AND CSO | 20,000 0.0648% | $15.23 | $304,646 | -66.40% | ||
| 2021-03-16 | Sale | Chief Medical Officer | 439 0.0015% | $15.09 | $6,626 | -19.03% | ||
| 2021-03-15 | Sale | Chief Medical Officer | 13,000 0.0427% | $15.10 | $196,269 | -20.52% | ||
| 2021-02-17 | Sale | Chief Medical Officer | 4,274 0.0142% | $15.05 | $64,345 | -17.94% | ||
| 2021-02-16 | Sale | Chief Medical Officer | 16,000 0.0525% | $15.15 | $242,422 | -19.24% | ||
| 2021-01-20 | Sale | Chief Medical Officer | 2,720 0.0093% | $15.07 | $40,980 | -13.79% | ||
| 2021-01-20 | Chief Medical Officer | 5,440 0.0187% | $15.07 | $81,959 | -13.79% |
Insider Historical Profitability
| PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 164578 0.2598% | $1.01 | 7 | 0 | +4.56% |
| Fletcher Aaron G.L. | 940000 1.4838% | $1.01 | 4 | 0 | <0.0001% | |
| Gray Cameron | director | 677500 1.0695% | $1.01 | 2 | 0 | <0.0001% |
| Suri Anish | PRESIDENT AND CSO | 135638 0.2141% | $1.01 | 2 | 6 | +73.75% |
| DIGIANDOMENICO ANTHONY | director | 57000 0.09% | $1.01 | 5 | 0 | +68.36% |
Institutional Investor Ownership
| Bleichroeder Lp | $5.21M | 5.66 | 2.76M | +56.98% | +$1.89M | 1.36 | |
| Slate Path Capital LP | $4.54M | 4.94 | 2.4M | 0% | +$0 | 0.09 | |
| The Vanguard Group | $4.32M | 4.69 | 2.28M | +7.05% | +$284,363.72 | <0.0001 | |
| BlackRock | $4.24M | 4.61 | 2.24M | -4.05% | -$178,911.15 | <0.0001 | |
| Geode Capital Management | $1.59M | 1.72 | 838,531 | +3.1% | +$47,721.55 | <0.0001 |